OLARATUMAB- (SOFT TISSUE SARCOMA)

^ Nivolumab-Ipilimumab (Melanoma) see Ipilimumab-Nivolumab (Mela- noma) on page 2157 ^ Obinutuzumab- (NHL-Follicular) see Bendamustine-Obinu- tuzumab (NHL-Follicular) on page 1986 ^ Obinutuzumab- (CLL) see Chlorambucil-Obinutuzumab (CLL) on page 2034 ^ OFA-FC (CLL) see Fludarabine-- (CLL) on page 2119 OFAR (CLL) Index Terms -Fludarabine-- (CLL) Use , chronic lymphocytic Regimen Cycle 1: Oxaliplatin: IV: 25 mg/m2/dose day 1 to 4 [total dose/cycle = 100 mg/m2] Fludarabine: IV: 30 mg/m2/dose days 2 and 3 [total dose/cycle = 60 mg/m2] Cytarabine: IV: 1000 mg/m2/dose over 2 hours days 2 and 3 [total dose/cycle = 2000 mg/m2] Rituximab: IV: 375 mg/m2 day 3 [total dose/cycle = 375 mg/m2] Treatment cycle is 4 weeks Cycles 2-6: Oxaliplatin: IV: 25 mg/m2/dose day 1 to 4 [total dose/cycle = 100 mg/m2] Fludarabine: IV: 30 mg/m2/dose days 2 and 3 [total dose/cycle = 60 mg/m2] Cytarabine: IV: 1000 mg/m2/dose over 2 hours days 2 and 3 [total dose/cycle = 2000 mg/m2] Rituximab: IV: 375 mg/m2 day 1 [total dose/cycle = 375 mg/m2] Repeat cycle every 4 weeks (maximum: 6 cycles) References Tsimberidou AM, Wierda WG, Plunkett W, et al, "Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy in Patients With Richter's Syndrome or Fludarabine-Refractory Chronic Lymphocytic Leukemia," J Clin Oncol, 2008, 26(2):196-203. ^ Ofatumumab-Chlorambucil (CLL) see Chlorambucil-Ofatumumab (CLL) on page 2034 ^ Ofatumumab-Fludarabine-Cyclophosphamide (CLL) see Fludarabine- Cyclophosphamide-Ofatumumab (CLL) on page 2119 Olaratumab-Doxorubicin (Soft Tissue Sarcoma) Index Terms Doxorubicin-Olaratumab (Soft Tissue Sarcoma) Use Soft tissue sarcoma (unresectable or metastatic) Regimen NOTE: Patients were permitted to receive dexrazoxane in cycles 5 to 8 Cycles 1 to 8: Olaratumab: IV: 15 mg/kg over 60 minutes days 1 and 8 [total dose/cycle = 30 mg/kg]

2181 OLARATUMAB-DOXORUBICIN (SOFT TISSUE SARCOMA)

Doxorubicin: IV: 75 mg/m2 day 1 [total dose/cycle = 75 mg/m2] Repeat cycle every 21 days for a total of 8 cycles Followed by (in the absence of disease progression or unacceptable toxicity) Olaratumab: IV: 15 mg/kg/day over 60 minutes days 1 and 8 [total dose/cycle = 30 mg/kg] Repeat cycle every 21 days until disease progression or unacceptable toxicity References Tap WD, Jones RL, Van Tine BA, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016;388(10043):488-497. ^ Oxaliplatin- (Biliary Cancer) see CAPOX (Biliary Cancer) on page 2010 ^ Oxaliplatin-Capecitabine (Colorectal) see XELOX (Colorectal) on page 2233 ^ Oxaliplatin-Capecitabine- (Gastric/Esophageal) see Epirubi- cin-Oxaliplatin-Capecitabine (Gastric/Esophageal) on page 2104 ^ Oxaliplatin-Capecitabine (Gastric) see Capecitabine-Oxaliplatin (Gastric) on page 2009 ^ Oxaliplatin-Capecitabine (Pancreatic) see CAPOX (Pancreatic) on page 2011 ^ Oxaliplatin-Capecitabine (Unknown Primary, Adenocarcinoma) see Capecitabine-Oxaliplatin (Unknown Primary, Adenocarcinoma) on page 2009 ^ Oxaliplatin--Leucovorin- (Esophageal Cancer) see Docetaxel-Oxaliplatin-Leucovorin-Fluorouracil (Esophageal Cancer) on page 2093 ^ Oxaliplatin-Fludarabine-Cytarabine-Rituximab (CLL) see OFAR (CLL) on page 2181 ^ Oxaliplatin-Fluorouracil-Epirubicin (Gastric/Esophageal) see Epirubicin- Oxaliplatin-Fluorouracil (Gastric/Esophageal) on page 2105 ^ Oxaliplatin-Fluorouracil-Leucovorin-Bevacizumab (Colorectal) see Bev- acizumab FOLFOX (Colorectal) on page 1993 ^ Oxaliplatin, Fluorouracil, Leucovorin (Pancreatic) see FOLFOX (Pancre- atic) on page 2133 ^ Oxaliplatin-- (Testicular) see Gemcitabine-Oxali- platin-Paclitaxel (Testicular) on page 2137 ^ Oxaliplatin-Gemcitabine-Rituximab (NHL-DLBCL) see GEMOX-R (NHL- DLBCL) on page 2141 ^ Oxaliplatin-Gemcitabine-Rituximab (NHL-Mantle Cell) see GEMOX-R (NHL-Mantle Cell) on page 2141 ^ Oxaliplatin-Gemcitabine (Testicular) see GEMOX (Testicular) on page 2142 ^ Oxaliplatin--Fluorouracil-Leucovorin (Pancreatic) see FOL- FIRINOX (Pancreatic) on page 2129 ^ Oxaliplatin-Leucovorin-Fluorouracil (Colorectal) see FLOX (Colorectal) on page 2116

2182